Use of UAP inhibitors to inhibit flux through the hexosamine biosynthetic pathway

A pharmaceutical composition comprising 1) a therapeutically effective amount of a compound of the following formula or pharmaceutically acceptable salt, solvate, anomers or hydrate thereof and 2 a pharmaceutically acceptable carrier:

• wherein X is CO, SO2 or CH2;
• R6, R7, R8, R9, are each independently H or CO(CH2)nCH3;
• n is 0-16;
• R is
• wherein V, W, X, Y, Z are, each independently, C or N,
• R1, R2, R3, R4, R5 are, each independently, —H, —(CH2)nCH3 where m=0-6, —Br, —Cl, —F, —I, —NH2, —SH, —NO2, —NHSO2Ra where Ra is alkyl or branched alkyl, —SO2NHRb where Rb is alkyl or branched alkyl, —OH, —ORc where Rc is alkyl or branched alkyl or alkyl ester, —NHRd where Rd is alkyl or branched alkyl or amide, —OCF3, —COOH, or —COORe where Re is alkyl or branched alkyl, i is 0, k is 1 to 10, and
• a pharmaceutically acceptable carrier.